September 27, 2024 Denmark’s Novo Nordisk A/S, the obesity drug first mover, risks being outgrown by U.S. rival Eli Lilly & Co. Previous Post Mexico Cenbank Cuts Interest Rate by 25 bp, Inflation Cools Next Post Oil Steady, on Track for Weekly Drop on Firmer Supply Outlook
